Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Cipla moves against...

    Cipla moves against NPPA for price fixation of asthma drugs; DOP junks plea

    Farhat NasimWritten by Farhat Nasim Published On 2019-06-16T11:44:25+05:30  |  Updated On 16 Aug 2021 11:40 AM IST

    New Delhi: Mumbai-based drugmaker, Cipla Limited's review petition against the Government regulatory agency, National Pharmaceutical Pricing Authority (NPPA) for fixing the price of its formulations Budesonide Inhalation (DPI) 200mcg/dose, Budesonide (A) + Formoterol (B) Inhalation (DPI) 100mcg (A)/200 mcg(A)/400 mcg(A) + 6 mcg (B) and Tiotropium Inhalation (DPI) 18 mcg/dose, Budesonide Inhalation (MDI) 200mcg/dose and Tiotropium Inhalation (MDI) 9 mcg/dose has recently been disposed of by the Department of Pharmaceuticals (DoP).


    The said formulations include Tiotropium which is used to treat lung diseases such as asthma and COPD (bronchitis, emphysema) while Budesonide is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma.


    The move comes following a petition filed by the drugmaker earlier this year under paragraph 31 of the Drugs Prices Control Order (DPCO), 2013.


    However, DoP rejected the petition observing that the company has not implemented the ceiling prices notification of the formulations before filing the review applications.


    Challenging DoP, Cipla had stated that the review applications of Glenmark and Lupin for review of the price of Metered Dose Inhalers (MDI)/Dry Powder Inhalers (DPI) were earlier considered by the authority even though the applicants had not implemented the notified prices.


    In response to this, DoP said that the hearings were given to Glenmark and Lupin on the ground that NPPA had not earlier fixed the ceiling price of DPI formulations and wrongfully inserted it in notification giving an impact of Wholesale Price Index.


    "Considering the merit of their cases, the Department of Pharmaceuticals had granted hearing to those companies at that time," states DoP.


    According to DoP, in the instant matter, NPPA has fixed the ceiling price of DPI formulations, and therefore this case is not similar to the cases referred to by the applicant.


    As per Para 31 of DPCO, 2013, it is mandatory for the applicant company to implement the ceiling price of the formulation before filing the review petition.


    Nothing the same, DoP has rejected the review applications filed by Cipla.


    Also Read: DOP rejects Review Petition of Lupin against ceiling price fixation for its combinations

    asthmaasthma drugbreathing problemBudesonideBudesonide inhalationCiplaDepartment of PharmaceuticalsDOPDPCODPIdrugmakerDrugs Prices Control Orderdry powder inhalersGlenmarkinhalationLupinMDIMumbaiNational Pharmaceutical Pricing AuthorityNPPATiotropiumTiotropium InhalationWholesale Price Index. Metered Dose Inhalers

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok